Lantheus Holdings (LNTH)

Executive Summary

Lantheus Holdings is a commercial-stage biopharmaceutical company specializing in diagnostic imaging agents and radiopharmaceutical therapeutics for cardiovascular disease and cancer. Its commercial portfolio includes DEFINITY® for ultrasound and PYLARIFY® for PET imaging in prostate cancer, providing a stable revenue base. The company's pipeline features approximately 40 drug candidates, with a focus on targeted radiopharmaceuticals and imaging technologies. Key programs include LNTH2403 for relapsed/refractory osteosarcoma (Phase 1/2) and ongoing studies expanding PYLARIFY into additional indications. Lantheus' integrated business model, from R&D through commercialization, positions it for growth in the precision medicine and radiopharmaceutical space. With strong commercial products and a promising early-stage pipeline, the company is well-poised to capitalize on the expanding radiopharmaceutical market.

Upcoming Catalysts (preview)

• Q3 2026PYLARIFY prostate cancer trial completion (NCT06074510) with potential label expansion80% success
• H2 2026LNTH2403 Phase 1/2 initial efficacy data in relapsed/refractory osteosarcoma30% success
• TBDRegulatory updates on PYLARIFY for other indications (e.g., renal cell carcinoma)40% success